The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Statins for the primary prevention of cardiovascular disease
Open accessAbstract
BACKGROUND: Reducing high blood cholesterol, a risk factor for cardiovascular disease (CVD) events in people with and without a past history of coronary heart disease (CHD) is an important goal of pharmacotherapy. Statins are the first-choice agents. Previous reviews of the effects of statins have highlighted their benefits in people with coronary artery disease. The case for primary prevention, however, is less clear. OBJECTIVES: To assess the effects, both harms and benefits, of statins in people with no history of CVD. SEARCH STRATEGY: To avoid duplication of effort, we checked reference lists of previous systematic reviews. We searched the Cochrane Central Register of Controlled Trials (Issue 1, 2007), MEDLINE (2001 to March 2007) and EMBASE (2003 to March 2007). There were no language restrictions. SELECTION CRITERIA: Randomised controlled trials of statins with minimum duration of one year and follow-up of six months, in adults with no restrictions on their total low density lipoprotein (LDL) or high density lipoprotein (HDL) cholesterol levels, and where 10% or less had a history of CVD, were included. DATA COLLECTION AND ANALYSIS: Two authors independently selected studies for inclusion and extracted data. Outcomes included all cause mortality, fatal and non-fatal CHD, CVD and stroke events, combined endpoints (fatal and non-fatal CHD, CVD and stroke events), change in blood total cholesterol concentration, revascularisation, adverse events, quality of life and costs. Relative risk (RR) was calculated for dichotomous data, and for continuous data pooled weighted mean differences (with 95% confidence intervals) were calculated. MAIN RESULTS: Fourteen randomised control trials (16 trial arms; 34,272 participants) were included. Eleven trials recruited patients with specific conditions (raised lipids, diabetes, hypertension, microalbuminuria). All-cause mortality was reduced by statins (RR 0.83, 95% CI 0.73 to 0.95) as was combined fatal and non-fatal CVD endpoints (RR 0.70, 95% CI 0.61 to 0.79). Benefits were also seen in the reduction of revascularisation rates (RR 0.66, 95% CI 0.53 to 0.83). Total cholesterol and LDL cholesterol were reduced in all trials but there was evidence of heterogeneity of effects. There was no clear evidence of any significant harm caused by statin prescription or of effects on patient quality of life. AUTHORS' CONCLUSIONS: Although reductions in all-cause mortality, composite endpoints and revascularisations were found with no excess of adverse events, there was evidence of selective reporting of outcomes, failure to report adverse events and inclusion of people with cardiovascular disease. Only limited evidence showed that primary prevention with statins may be cost effective and improve patient quality of life. Caution should be taken in prescribing statins for primary prevention among people at low cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Selected major risk factors and global and regional burden of disease
Ezzati, M., Lopez, A. D., Rodgers, A., Vander Hoorn, S., & Murray, C. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11403-6 · Cited by 3,594
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Yusuf, S., Reddy, S., Ôunpuu, S., & Anand, S. (2001) · Circulation · doi:10.1161/hc4601.099487 · Cited by 2,972
Systematic Reviews: Identifying relevant studies for systematic reviews
Dickersin, K., Scherer, R., & Lefebvre, C. (1994) · BMJ · doi:10.1136/bmj.309.6964.1286 · Cited by 2,256
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720
Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106283442601 · Cited by 1,557
The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.23.2998 · Cited by 1,331
Effect of Statins on Risk of Coronary Disease: A Meta-analysis of Randomized Controlled Trials
LaRosa, J. C., He, J., & Vupputuri, S. (1999) · JAMA · doi:10.1001/jama.282.24.2340 · Cited by 1,246
Anderson, T. J., Meredith, I. T., Yeung, A. C., Frei, B., Selwyn, A. P., & Ganz, P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502233320802 · Cited by 1,109
Jones, P., Kafonek, S., Laurora, I., & Hunninghake, D. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00965-x · Cited by 1,067
Buchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001
Aggressive Lipid-Lowering Therapy Compared with Angioplasty in Stable Coronary Artery Disease
Pitt, B., Waters, D., Brown, W. V., van Boven, A. J., Schwartz, L., Title, L. M., Eisenberg, D., Shurzinske, L., & McCormick, L. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199907083410202 · Cited by 946
Furberg, C. D., Adams, H. P., Applegate, W. B., Byington, R. P., Espeland, M. A., Hartwell, T., Hunninghake, D. B., Lefkowitz, D. S., Probstfield, J., & Riley, W. A. (1994) · Circulation · doi:10.1161/01.cir.90.4.1679 · Cited by 867
(1998) · Circulation · doi:10.1161/01.cir.97.15.1440 · Cited by 796
Brugts, J. J., Yetgin, T., Hoeks, S. E., Gotto, A. M., Shepherd, J., Westendorp, R. G. J., de Craen, A. J. M., Knopp, R. H., Nakamura, H., Ridker, P., et al. (2009) · BMJ · doi:10.1136/bmj.b2376 · Cited by 792
Als-Nielsen, B., Chen, W., Gluud, C., & Kjaergard, L. L. (2003) · JAMA · doi:10.1001/jama.290.7.921 · Cited by 746
Statins and Cancer Risk: A Meta-analysis
Dale, K. M., Coleman, C. I., Henyan, N. N., Kluger, J., & White, C. M. (2006) · JAMA · doi:10.1001/jama.295.1.74 · Cited by 599
Egashira, K., Hirooka, Y., Kai, H., Sugimachi, M., Suzuki, S., Inou, T., & Takeshita, A. (1994) · Circulation · doi:10.1161/01.cir.89.6.2519 · Cited by 597
A systematic review and economic evaluation of statins for the prevention of coronary events
Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., & Payne, N. (2007) · Health Technology Assessment · doi:10.3310/hta11140 · Cited by 556
Knopp, R. H., d’Emden, M., Smilde, J. G., Pocock, S. J., & on behalf of the ASPEN Study Group (2006) · Diabetes Care · doi:10.2337/dc05-2415 · Cited by 550
Salonen, R., Nyyssönen, K., Porkkala, E., Rummukainen, J., Belder, R., Park, J.-S., & Salonen, J. T. (1995) · Circulation · doi:10.1161/01.cir.92.7.1758 · Cited by 540
Chen, Z., Peto, R., Collins, R., MacMahon, S., Lu, J., & Li, W. (1991) · BMJ · doi:10.1136/bmj.303.6797.276 · Cited by 537
Effects of Fosinopril and Pravastatin on Cardiovascular Events in Subjects With Microalbuminuria
Asselbergs, F. W., Diercks, G. F. H., Hillege, H. L., van Boven, A. J., Janssen, W. M. T., Voors, A. A., de Zeeuw, D., de Jong, P. E., van Veldhuisen, D. J., & van Gilst, W. H. (2004) · Circulation · doi:10.1161/01.cir.0000146378.65439.7a · Cited by 523
Mohler, E. R., Hiatt, W. R., & Creager, M. A. (2003) · Circulation · doi:10.1161/01.cir.0000090686.57897.f5 · Cited by 479
Risks Associated With Statin Therapy: A Systematic Overview of Randomized Clinical Trials
Kashani, A., Phillips, C. O., Foody, J. M., Wang, Y., Mangalmurti, S., Ko, D. T., & Krumholz, H. M. (2006) · Circulation · doi:10.1161/circulationaha.106.624890 · Cited by 474
Investigating and Dealing with Publication and Other Biases
Sterne, J. A. C., Egger, M., & Smith, G. D. (2001) · Systematic Reviews in Health Care · doi:10.1002/9780470693926.ch11 · Cited by 449
Self-citationThe design of a prospective study of pravastatin in the elderly at risk (PROSPER)
Shepherd, J., Blauw, G. J., Murphy, M. B., Cobbe, S. M., Bollen, E. L. E. M., Buckley, B. M., Ford, I., Jukema, J. W., Hyland, M., Gaw, A., et al. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00533-0 · Cited by 449
Ray, K. K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.182 · Cited by 446
Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments
Mills, E. J., Rachlis, B., Wu, P., Devereaux, P. J., Arora, P., & Perri, D. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.039 · Cited by 423
Lim, S. S., Gaziano, T. A., Gakidou, E., Reddy, K. S., Farzadfar, F., Lozano, R., & Rodgers, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61699-7 · Cited by 372
Bradford, R. H. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400010067008 · Cited by 372
Thavendiranathan, P. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.21.2307 · Cited by 351
Hedblad, B., Wikstrand, J., Janzon, L., Wedel, H., & Berglund, G. (2001) · Circulation · doi:10.1161/01.cir.103.13.1721 · Cited by 325
Berry, J. D., Liu, K., Folsom, A. R., Lewis, C. E., Carr, J. J., Polak, J. F., Shea, S., Sidney, S., O'Leary, D. H., Chan, C., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.800235 · Cited by 318
Blauw, G. J., Lagaay, A. M., Smelt, A. H. M., & Westendorp, R. G. J. (1997) · Stroke · doi:10.1161/01.str.28.5.946 · Cited by 311
Plasma cholesterol concentration and mortality. The Whitehall Study
Smith, G. D. (1992) · JAMA · doi:10.1001/jama.267.1.70 · Cited by 306
Cheung, B. M. Y., Lauder, I. J., Lau, C., & Kumana, C. R. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2003.02060.x · Cited by 304
Reducing The Growing Burden Of Cardiovascular Disease In The Developing World
Gaziano, T. A. (2007) · Health Affairs · doi:10.1377/hlthaff.26.1.13 · Cited by 304
Effects of lovastatin on cognitive function and psychological well-being
Muldoon, M. F., Barger, S. D., Ryan, C. M., Flory, J. D., Lehoczky, J. P., Matthews, K. A., & Manuck, S. B. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00353-3 · Cited by 290
Statin-related adverse events: A meta-analysis
Silva, M. A., Swanson, A. C., Gandhi, P. J., & Tataronis, G. R. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.01.005 · Cited by 278
Effectiveness of Statin Therapy in Adults With Coronary Heart Disease
Wilt, T. J., Bloomfield, H. E., MacDonald, R., Nelson, D., Rutks, I., Ho, M., Larsen, G., McCall, A., Pineros, S., & Sales, A. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.13.1427 · Cited by 275
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., McInnes, G. T., Mehlsen, J., et al. (2001) · Journal of Hypertension · doi:10.1097/00004872-200106000-00020 · Cited by 264
Pignone, M. (2000) · BMJ · doi:10.1136/bmj.321.7267.983 · Cited by 259
Mercuri, M., Bond, M. G., Sirtori, C. R., Veglia, F., Crepaldi, G., Saverio Feruglio, F., Descovich, G., Ricci, G., Rubba, P., Mancini, M., et al. (1996) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00333-6 · Cited by 253
The causes and effects of socio-demographic exclusions from clinical trials
Bartlett, C., Doyal, L., Ebrahim, S., Davey, P., Bachmann, M., Egger, M., & Dieppe, P. (2005) · Health Technology Assessment · doi:10.3310/hta9380 · Cited by 250
Self-citationDavidson, M., McKenney, J., Stein, E., Schrott, H., Bakker-Arkena, R., Fayyad, R., & Black, D. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00174-4 · Cited by 233
Sawayama, Y., Shimizu, C., Maeda, N., Tatsukawa, M., Kinukawa, N., Koyanagi, S., Kashiwagi, S., & Hayashi, J. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01783-1 · Cited by 226
McDermott, M. M., Guralnik, J. M., Greenland, P., Pearce, W. H., Criqui, M. H., Liu, K., Taylor, L., Chan, C., Sharma, L., Schneider, J. R., et al. (2003) · Circulation · doi:10.1161/01.cir.0000050380.64025.07 · Cited by 222
Caro, J., Klittich, W., McGuire, A., Ford, I., Norrie, J., Pettitt, D., McMurray, J., & Shepherd, J. (1997) · BMJ · doi:10.1136/bmj.315.7122.1577 · Cited by 203
(1993) · The American Journal of Cardiology · doi:10.1016/0002-9149(93)90858-a · Cited by 182
Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials
Muldoon, M. F. (2001) · BMJ · doi:10.1136/bmj.322.7277.11 · Cited by 181
Dangas, G., Badimon, J. J., Smith, D. A., Unger, A. H., Levine, D., Shao, J. H., Meraj, P., Fier, C., Fallon, J. T., & Ambrose, J. A. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00018-2 · Cited by 180
Ramsay, L., Haq, I., Jackson, P., Yeo, W., Pickin, D., & Payne, J. (1996) · The Lancet · doi:10.1016/s0140-6736(96)05516-x · Cited by 168
Changes in Sequential Coronary Arteriograms and Subsequent Coronary Events
Buchwald, H. (1992) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1992.03490110067031 · Cited by 168
Testing cognitive function in elderly populations: the PROSPER study
Houx, P. J., Shepherd, J. P., Blauw, G.-J., Murphy, M. B., Ford, I., Bollen, E. L. E. M., Buckley, B. M., Stott, D. J., Jukema, J. W., Hyland, M. E., et al. (2002) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.73.4.385 · Cited by 155
Zanchetti, A., Crepaldi, G., Bond, M. G., Gallus, G., Veglia, F., Mancia, G., Ventura, A., Baggio, G., Sampieri, L., Rubba, P., et al. (2004) · Stroke · doi:10.1161/01.str.0000147041.00840.59 · Cited by 154
Variations and increase in use of statins across Europe: data from administrative databases
Walley, T., Folino-Gallo, P., Schwabe, U., & Ganse, E. H. V. (2004) · BMJ · doi:10.1136/bmj.328.7436.385 · Cited by 143
Vrecer, M., Turk, S., Drinovec, J., & Mrhar, A. (2003) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp41567 · Cited by 143
Briel, M., Studer, M., Glass, T. R., & Bucher, H. C. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.04.022 · Cited by 143
What role for statins? A review and economic model.
Ebrahim, S. B. J., Smith, G. D., McCabe, Payne, Pickin, Sheldon, T., Lampe, F. C., Sampson, F. C., Ward, S. E., & Wannamethee, S. G. (1999) · Health Technology Assessment · doi:10.3310/hta3190 · Cited by 139
Self-citationJardine, A. G., Holdaas, H., Fellström, B., Cole, E., Nyberg, G., Grönhagen‐Riska, C., Madsen, S., Neumayer, H., Maes, B., Ambühl, P. M., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2004.00445.x · Cited by 125
Anderssen, S. A., Hjelstuen, A., Hjermann, I., Bjerkan, K. K., & Holme, I. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.08.033 · Cited by 122
Cobbe, S. M. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(96)00863-6 · Cited by 118
Long-term safety and efficacy profile of simvastatin
Boccuzzi, S. J., Bocanegra, T. S., Walker, J. F., Shapiro, D. R., & Keegan, M. E. (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90182-k · Cited by 115
Bradford, R. H., Shear, C. L., Chremos, A. N., Dujovne, C. A., Franklin, F. A., Grillo, R. B., Higgins, J., Langendörfer, A., Nash, D. T., Pool, J. L., et al. (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90307-7 · Cited by 109
Are lipid-lowering guidelines evidence-based?
Abramson, J. D., & Wright, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60084-1 · Cited by 106
Santanello, N. C., Barber, B., Applegate, W. B., Elam, J. T., Curtis, C., Hunninghake, D. B., Gordon, D. J., & For the CRISP Collaborative Study Group (1997) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1997.tb00971.x · Cited by 101
Lemaître, R. N., Psaty, B. M., Heckbert, S. R., Kronmal, R. A., Newman, A. B., & Burke, G. L. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.12.1395 · Cited by 99
A coronary primary prevention study of Scottish men aged 45?64 years: Trial design
(1992) · Journal of Clinical Epidemiology · doi:10.1016/0895-4356(92)90068-x · Cited by 98
Thomas, M. E., Harris, K. P. G., Ramaswamy, C., Hattersley, J., Wheeler, D. C., Varghese, Z., Williams, J. D., Walls, J., & Moorhead, J. F. (1993) · Kidney International · doi:10.1038/ki.1993.358 · Cited by 95
Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with Type 2 diabetes
Colhoun, H. M., Thomason, M. J., Mackness, M., Maton, S., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A. W., Fuller, J., & the CARDS Investigators (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00643.x · Cited by 92
Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration
Wardle, J., Armitage, J., Collins, R., Wallendszus, K., KEECH, A. C., & Lawson, A. (1996) · BMJ · doi:10.1136/bmj.313.7049.75 · Cited by 90
Taking simvastatin in the morning compared with in the evening: randomised controlled trial
Wallace, A., Chinn, D., & Rubin, G. P. (2003) · BMJ · doi:10.1136/bmj.327.7418.788 · Cited by 87
The impact of health care advice given in primary care on cardiovascular risk
Lindholm, L., Ekbom, T., Dash, C., Eriksson, M., Tibblin, G., & Scherstén, B. (1995) · BMJ · doi:10.1136/bmj.310.6987.1105 · Cited by 81
The West of Scotland Coronary Prevention Study Group (1997) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015165 · Cited by 80
Derosa, G., Mugellini, A., Ciccarelli, L., & Fogari, R. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80070-x · Cited by 78
Su, S., Hsiao, C.-L., Chu, C.-W., Lee, B.-C., & Lee, T. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01004-3 · Cited by 76
Noji, Y., Higashikata, T., Inazu, A., Nohara, A., Ueda, K., Miyamoto, S., Kajinami, K., Takegoshi, T., Koizumi, J., & Mabuchi, H. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00765-1 · Cited by 74
Buchwald, H., Campos, C. T., Boen, J. R., Nguyen, P. A., & Williams, S. E. (1995) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(95)80006-3 · Cited by 69
Expanding the Orbit of Primary Prevention — Moving beyond JUPITER
Hlatky, M. A. (2008) · New England Journal of Medicine · doi:10.1056/nejme0808320 · Cited by 69
Sasaki, J., & Arakawa, K. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)80166-5 · Cited by 66
Gentile, S., Turco, S., Guarino, G., Sasso, F. C., Amodio, M., Magliano, P. L., Salvatore, T., Corigliano, G., Agrusta, M., SIMONE, G. D., et al. (2000) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2000.00106.x · Cited by 66
Bartlett, C., Davey, P., Dieppe, P. A., Doyal, L., Ebrahim, S. B. J., & Egger, M. (2003) · Heart · doi:10.1136/heart.89.3.327 · Cited by 65
Self-citationOnce‐daily pravastatin in patients with primary hypercholesterolemia: A dose‐response study
Jones, P. H., Farmer, J. A., Cressman, M. D., McKenney, J. M., Wright, J. T., Proctor, J. D., Berkson, D. M., Farnham, D. J., Wolfson, P. M., Colfer, H. T., et al. (1991) · Clinical Cardiology · doi:10.1002/clc.4960140211 · Cited by 65
Cholesterol and coronary heart disease: screening and treatment
Ebrahim, S. B. J., Smith, G. D., McCabe, C. J., Payne, N., Pickin, M., Sheldon, T., Lampe, F. C., Sampson, F. C., Ward, S. E., & Wannamthee, G. (1998) · BMJ Quality & Safety · doi:10.1136/qshc.7.4.232 · Cited by 64
Self-citationSystematic reviewers neglect bias that results from trials stopped early for benefit
Bassler, D., González, I. F., Briel, M., Cook, D. J., Devereaux, P. J., Heels-Ansdell, D., Kirpalani, H. M., Meade, M. O., Montori, V. M., Rozenberg, A., et al. (2007) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.12.006 · Cited by 63
Eriksson, M., Hådell, K., Holme, I., Walldius, G., & Kjellström, T. (1998) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1998.00294.x · Cited by 61
Serum total cholesterol and risk of hospitalization, and death from respiratory disease
Iribarren, C., Jacobs, D. R., Sidney, S., Claxton, A. J., Gross, M. D., Sadler, M., & Blackburn, H. (1997) · International Journal of Epidemiology · doi:10.1093/ije/26.6.1191 · Cited by 59
Low-Dose Combined Therapy with Fluvastatin and Cholestyramine in Hyperlipidemic Patients
Sprecher, D. L., Abrams, J., Allen, J. W., Keane, W. F., Chrysant, S. G., Ginsberg, H. N., Fischer, J. J., Johnson, B. F., Théroux, P., & Jokubaitis, L. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-120-7-199404010-00002 · Cited by 55
Katerndahl, D. A., & Lawler, W. R. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009830 · Cited by 55
Simvastatin in nephrotic syndrome
Olbricht, C. J., for the Simvastatin In Nephrotic Syndrome Study Group, Wanner, C., Thiery, J., & Basten, A. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.07128.x · Cited by 55
Stein, E. A., Sprecher, D. L., Allenby, K. S., Tosiello, R. L., Whalen, E., & Ripa, S. (1997) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424849700200102 · Cited by 53
Cholesterol, M. O. E. (2004) · Circulation Journal · doi:10.1253/circj.68.860 · Cited by 52
Ford, I., Blauw, G. J., Murphy, M. B., Shepherd, J., Cobbe, S. M., Bollen, E. L. E. M., Buckley, B. M., Jukema, J. W., Hyland, M., Gaw, A., et al. (2002) · Current Controlled Trials in Cardiovascular Medicine · doi:10.1186/1468-6708-3-8 · Cited by 43
High-risk elderly patients PROSPER from cholesterol-lowering therapy
Collins, R., & Armitage, J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11650-3 · Cited by 42
Bradford, R. H., Shear, C. L., Chremos, A. N., Franklin, F. A., Nash, D. T., Hurley, D. P., Dujovne, C. A., Pool, J. L., Schnaper, H. W., Hesney, M., et al. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90052-y · Cited by 41
Baldassarre, D., Veglia, F., Gobbi, C., Gallus, G., Ventura, A., Crepaldi, G., Fisicaro, M., Rimondi, S., Ricci, G., Mancini, M., et al. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(99)00434-7 · Cited by 39
Statins for primary prevention: at what coronary risk is safety assured?
Jackson, P. R., Wallis, E. J., Haq, I. U., & Ramsay, L. E. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01478.x · Cited by 38
Bradford, R. H., Shear, C. L., Chremos, A. N., Dujovne, C. A., Franklin, F. A., Hesney, M., Higgins, J., Langendörfer, A., Pool, J. L., Schnaper, H. W., et al. (1990) · The American Journal of Cardiology · doi:10.1016/0002-9149(90)90440-c · Cited by 38
Behavioral Implications of Lowering Cholesterol Levels: A Double-Blind Pilot Study
Ormiston, T., Wolkowitz, O. M., Reus, V. I., & Manfredi, F. (2003) · Psychosomatics · doi:10.1176/appi.psy.44.5.412 · Cited by 35
Lindholm, L. H., Ekbom, T., Dash, C. H., Isacsson, Å., & Scherstén, B. (1996) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1996.492831000.x · Cited by 34
Effects of Lovastatin on the Immune System
Muldoon, M. F., Flory, J. D., Marsland, A. L., Manuck, S. B., Whiteside, T. L., & Rabin, B. S. (1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00695-4 · Cited by 33
Reduced Cholesterol Is Associated with Recent Minor Illness The CARDIA Study
Jacobs, D. R., Hebert, B., Schreiner, P. J., Sidney, S., Iribarren, C., & Hulley, S. B. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009314 · Cited by 33
Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis
Hufnagel, G., Michel, C., Vrtovsnik, F., Queffeulou, G., Kossari, N., & Mignon, F. (2000) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/15.5.684 · Cited by 32
Cassader, M., Ruiu, G., Gambino, R., Alemanno, N., Veglia, F., & Pagano, G. (1993) · Atherosclerosis · doi:10.1016/0021-9150(93)90049-z · Cited by 26
Randomized Trials Stopped Early for Benefit: A Systematic Review
Montori, V. M., Devereaux, P. J., Adhikari, N. K. J., Burns, K. E. A., Eggert, C. H., Briel, M., Lacchetti, C., Leung, T. W., Darling, E., Bryant, D. M., et al. (2005) · JAMA · doi:10.1001/jama.294.17.2203 · Cited by 26
Chan, P., Tomlinson, B., Lee, C.-B., Pan, W., & Lee, Y.-S. (1996) · Hypertension · doi:10.1161/01.hyp.28.4.647 · Cited by 25
Tanaka, A., Yamada, N., Saitō, Y., Kawakami, M., Ohashi, Y., & Akanuma, Y. (2001) · Clinica Chimica Acta · doi:10.1016/s0009-8981(01)00589-7 · Cited by 25
Buchwald, H., Campos, C. T., Matts, J. P., Fitch, L. L., Long, J. M., & Varco, R. L. (1992) · Annals of Surgery · doi:10.1097/00000658-199210000-00001 · Cited by 21
Bak, Huizer, Leijten, Rila, & Grobbee (1998) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1998.00350.x · Cited by 21
Duffy, S. J., O’Brien, R. C., New, G., Harper, R. W., & Meredith, I. T. (2001) · Clinical and Experimental Pharmacology and Physiology · doi:10.1046/j.1440-1681.2001.03458.x · Cited by 21
Saitō, Y., Shirai, K., SASAKI, N., Shinomiya, M., & Yoshida, S. (2002) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.9.99 · Cited by 19
Branchi, A., Rovellini, A., Fiorenza, A. M., & Sommariva, D. (1995) · PubMed · Cited by 18
Glasser, S. P., DiBianco, R., Effron, B. A., Faas, F. H., Germino, F. W., Shane, L. E., Unger, A. H., & Staggers, J. E. (1996) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)89140-0 · Cited by 15
The Kyushu Lipid Intervention Study Group (1996) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat1994.3.95 · Cited by 15
Preventing the next event in the elderly: the PROSPER perspective
Shepherd, J. (2003) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(03)90003-1 · Cited by 13
[The PROSPER Study (PROspective study of pravastatin in the elderly at risk)].
KULBERTUS, H. E., & Scheen, A. J. (2002) · PubMed · Cited by 12
Sirtori, C. R., Bianchi, G., Bond, M. G., D'Alò, G., Gallus, G., Liberatore, S., Mercuri, M. F., & Ventura, A. (1995) · International journal of cardiac imaging · doi:10.1007/bf01419825 · Cited by 10
Measuring the cost-effectiveness of lipid-lowering drugs in the elderly:
Avorn, J., Benner, J., Ford, I., Ganz, D. A., Gaw, A., Glynn, R. J., Jackson, J., Lagaay, A. M., Schneeweiß, S., Walley, T., et al. (2002) · Controlled Clinical Trials · doi:10.1016/s0197-2456(02)00228-3 · Cited by 9
Fiorenza, A. M., Sommariva, D., & Branchi, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12398-7 · Cited by 7
Blauw, G. J., Shepherd, J., & Murphy, M. B. (2001) · The Lancet · doi:10.1016/s0140-6736(05)71808-0 · Cited by 7
[Pravastatin in the treatment of primary hypercholesterolemia: a Swiss multicenter study].
Ferrari, P., Weidmann, P. U., Wf, R., Martius, F., Luban, S., Pasotti, E., Erné, P., Fragiacomo, C., Noseda, G., & Reutter, F. W. (1993) · PubMed · Cited by 6
K�bler, W. (2003) · Zeitschrift für Kardiologie · doi:10.1007/s00392-003-0967-7 · Cited by 4
Cattin, L., Col, P. G. D., Bordin, P., Battello, C., Petrucco, A., & Fonda, M. (1996) · Current Therapeutic Research · doi:10.1016/s0011-393x(96)80050-6 · Cited by 4
Anglo-Scandinavian cardiac outcomes trial : ASCOT : main protocol summary sub-study protocols
O'Brien, E. T. (2001) · Stockton Press eBooks · Cited by 3
Baztán, J. J., Hornillos, M. M., & Rodríguez‐Mañas, L. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12878-4 · Cited by 3
Ohta, H., Masuda, A., Fuyuki, T., Sugimoto, I., Suda, Y., Makita, K., Takamatsu, K., Horiguchi, F., & Nozawa, S. (2000) · Hormone Research in Paediatrics · doi:10.1159/000023559 · Cited by 3
Oi, K., & Komori, H. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(97)88689-3 · Cited by 2
[Statin therapy for hypertensive patients].
Svilaas, A., Kjeldsen, S. E., Midtbø, K., Westheim, A. S., & Syvertsen, J. O. (2004) · PubMed · Cited by 2
Pravastatin benefits elderly patients: results of PROSPER study.
(2003) · PubMed · Cited by 2
Cited by
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Collaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31829e8776 · Cited by 2,106
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Self-citation
Metadata
- Authors
- Taylor, F., Ward, K., Moore, T. H., Burke, M., Davey Smith, G., Casas, J. P., & Ebrahim, S.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2011-01-19
- Issue
- 1
- Pages
- CD004816-CD004816
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W4299310161
- Cited by
- 305
- References
- 144
- Type
- reference entry
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.